Identification of HER2-over-expression, HER2-low-expression, and HER2-zero-expression statuses in breast cancer based on 18F-FDG PET/CT radiomics

Table 2 Clinicopathological characteristics of BC patients enrolled in the external institution

Clinicopathologic Characteristic	External validation set (n = 100)
Clinicopathologic Characteristic	HER2-over (n = 25)	HER2-low (n = 45)	HER2-zero (n = 30)	p
Age	52.16 ± 8.89	54.98 ± 10.36	46.13 ± 10.81	0.002
SUVmax	13.15 ± 5.94	11.43 ± 7.62	13.67 ± 6.52	0.344
SUVmean	6.05 ± 1.68	4.97 ± 1.86	5.85 ± 1.60	0.025
ER				< 0.001
Positive	14(14.0%)	34(34.0%)	17(17.0%)
Negative	11(11.0%)	11(11.0%)	13(13.0%)
PR				< 0.001
Positive	11(11.0%)	29(29.0%)	15(15.0%)
Negative	14(14.0%)	16(16.0%)	15(15.0%)
Ki-67				0.064
≥ 14	25(25.0%)	40(40.0%)	28(28.0%)
< 14	0(0%)	5(5.0%)	2(2.0%)

Abbreviations: ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; SUV: standardized uptake value

ISSN: 1470-7330